Rituximab biosimilar - Mabion

Drug Profile

Rituximab biosimilar - Mabion

Alternative Names: MabionCD20

Latest Information Update: 26 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mabion
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Diffuse large B cell lymphoma; Rheumatoid arthritis

Most Recent Events

  • 12 Nov 2015 Mabion is planning a phase III trial in Diffuse large B-cell lymphoma in Bosnia and Herzegovina, Croatia, Georgia, Hungary, Moldova, Poland, Romania, Serbia and Ukraine (NCT02617485)
  • 23 Jun 2015 Biosimilars market licensed to Farmak, LYFIS, Sothema Laboratories, Laboratorio LKM and Onko-Kocsel Pharmaceuticals in multiple countries (Mabion website, June 2015)
  • 12 Sep 2014 Phase-III clinical trials in Diffuse large B cell lymphoma (In adults, In the elderly) in Croatia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top